A literature review of quetiapine for generalized anxiety disorder.

Item

http://www.wikidata.org/entity/Q38358483

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A literature review of quetiapine for generalized anxiety disorder.

@en

type

Item

label

A literature review of quetiapine for generalized anxiety disorder.

@en

prefLabel

A literature review of quetiapine for generalized anxiety disorder.

@en

P1476

A literature review of quetiapine for generalized anxiety disorder.

@en

P2093

Stephanie V Phan

http://www.w3.org/2001/XMLSchema#string

Tiffany-Jade M Kreys

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis.

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.

The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.

Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine.

P304

175-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1529

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25689246

http://www.w3.org/2001/XMLSchema#string